Sua seleção (0)
Detalhe da pesquisa
1.
Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth.
Cell;
167(5): 1281-1295.e18, 2016 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27863244
2.
The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt.
Blood;
134(Supplement_1): 28, 2019 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31723981
3.
Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update.
Blood;
134(Supplement_1): 30, 2019 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724000
4.
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Blood;
132(23): 2446-2455, 2018 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30287523
5.
Novel analytical methods to interpret large sequencing data from small sample sizes.
Hum Genomics;
13(1): 41, 2019 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31470908
6.
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Clin Cancer Res;
25(22): 6606-6613, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292142
7.
PAF promotes stemness and radioresistance of glioma stem cells.
Proc Natl Acad Sci U S A;
114(43): E9086-E9095, 2017 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29073105
8.
Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice.
Br J Haematol;
187(5): 615-626, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31394591
9.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood;
129(7): 846-854, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932374
10.
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
Haematologica;
104(6): 1150-1155, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573507
11.
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
Ann Hematol;
98(5): 1159-1168, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30798348
12.
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Cancer;
124(14): 2956-2963, 2018 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29723417
13.
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Cancer;
123(22): 4403-4410, 2017 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743166
14.
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
Cancer;
123(10): 1791-1799, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28026860
15.
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Haematologica;
102(8): 1368-1377, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522576
16.
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Haematologica;
102(1): 85-93, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27540137
17.
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lancet Oncol;
17(5): 612-21, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27083332
18.
Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.
Br J Haematol;
174(1): 71-80, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27060881
19.
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.
Am J Hematol;
91(4): 366-70, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26689746
20.
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood;
121(18): 3703-8, 2013 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23502220